Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.

Authors: Stine, Jessica E; Guo, Hui; Sheng, Xiugui; Han, Xiaoyun; Schointuch, Monica N; Gilliam, Timothy P; Gehrig, Paola A; Zhou, Chunxiao; Bae-Jump, Victoria L

Published In Oncotarget, (2016 Jan 05)

Abstract: Ovarian cancer is the 5th leading cause of cancer death among women in the United States. The mevalonate pathway is thought to be a potential oncogenic pathway in the pathogenesis of ovarian cancer. Simvastatin, a 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) inhibitor, is a widely used drug for inhibiting the synthesis of cholesterol and may also have anti-tumorigenic activity. Our goal was to evaluate the effects of simvastatin on ovarian cancer cell lines, primary cultures of ovarian cancer cells and in an orthotopic ovarian cancer mouse model. Simvastatin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, and caused cellular stress via reduction in the enzymatic activity of HMGCR and inhibition of the MAPK and mTOR pathways in ovarian cancer cells. Furthermore, simvastatin induced DNA damage and reduced cell adhesion and invasion. Simvastatin also exerted anti-proliferative effects on primary cell cultures of ovarian cancer. Treatment with simvastatin in an orthotopic mouse model reduced ovarian tumor growth, coincident with decreased Ki-67, HMGCR, phosphorylated-Akt and phosphorylated-p42/44 protein expression. Our findings demonstrate that simvastatin may have therapeutic benefit for ovarian cancer treatment and be worthy of further exploration in clinical trials.

PubMed ID: 26503475 Exiting the NIEHS site

MeSH Terms: Animals; Apoptosis/drug effects; Cell Adhesion/drug effects; Cell Line, Tumor; Cell Proliferation/drug effects; DNA Damage; Female; G1 Phase Cell Cycle Checkpoints/drug effects; Humans; Hydroxymethylglutaryl CoA Reductases/metabolism*; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology*; Immunoblotting; Mice, Knockout; Mitogen-Activated Protein Kinases/metabolism; Neoplasm Metastasis; Ovarian Neoplasms/drug therapy*; Ovarian Neoplasms/metabolism; Ovarian Neoplasms/pathology; Reactive Oxygen Species/metabolism; Signal Transduction/drug effects; Simvastatin/pharmacology*; TOR Serine-Threonine Kinases/metabolism; Xenograft Model Antitumor Assays*

Back
to Top